Gossamer Bio, Inc.
GOSSNASDAQHealthcare● Active
$0.17
$-0.01(-5.37%)
Market Cap$38865704
P/E Ratio—
52W High$3.87
52W Low$0.1625
Gossamer Bio, Inc. (GOSS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GOSS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($170.37M) | ($56.53M) | ($179.82M) | ($229.38M) | ($234.00M) |
| Depreciation & Amort. | $1.00M | $4.15M | $4.38M | $4.43M | $5.17M |
| Stock-Based Comp. | $10.55M | $20.62M | $28.52M | $42.55M | $32.01M |
| Change in Working Capital | ($13.63M) | $39.46M | ($14.84M) | ($4.46M) | $0.77M |
| Net Cash from Operations | ($171.27M) | ($3.47M) | ($159.16M) | ($187.03M) | ($188.89M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.08M) | $0.00M | $0.00M | ($0.47M) | ($1.62M) |
| Purchases of Investments | ($227.11M) | ($494.78M) | ($441.67M) | ($238.06M) | ($152.03M) |
| Sales of Investments | $383.54M | $523.80M | $330.70M | $237.50M | $36.23M |
| Net Cash from Investing | $156.36M | $29.02M | ($110.97M) | ($1.03M) | ($117.43M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.63M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($12.58M) | ($11.61M) | ($5.81M) | $0.00M |
| Net Cash from Financing | $6.42M | ($11.49M) | $190.15M | $117.09M | $3.33M |
| Free Cash Flow | |||||
| Free Cash Flow | ($171.34M) | ($3.47M) | ($159.16M) | ($187.51M) | ($190.51M) |
| FCF Margin %(computed) | -353.50% | -3.02% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Gossamer Bio, Inc. data
About Gossamer Bio, Inc. (GOSS) Cash Flow Statement
Gossamer Bio, Inc. generated operating cash flow of ($0.17B) and free cash flow of ($0.17B) for 2025 — a FCF margin of -353.50%. Capital expenditure was ($0.00B).
Frequently asked questions
GOSS · 4 questionsGossamer Bio, Inc. generated free cash flow of ($0.17B) for 2025, down 4840.7% year-over-year.
GOSS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10